Predictions for the Generic Drug Sector in 2018

PCI Synthesis shares expected trends in the industry within the next year

Posted: January 9, 2018

Author:
Tags: Articles | Contract Pharam
API Manufacturing and Pharmaceutical Manufacturing

Contract Pharma published PCI Synthesis’s Predictions for the Generic Drug Sector in 2018. Here are some of the trends that PCI Synthesis shared, which they expect will impact the industry next year

Read the Full Article and watch the video »

Related posts:

State Needs to Recognize Biotech Evolution
2015 Trends and Predictions for API Drug Manufacturing
What’s Driving the CMO Market? – The Opportunities and Challenges Ahead
What’s The Real Answer to Rising Costs of Blockbuster Drugs? Competition
The Long Paper Trail of Documentation in API Manufacturing

About the Author

Ed Price CEO of PCI Synthesis
Ed is President & CEO of SEQENS North America (formerly PCI Synthesis). He serves as a co-chair of the New England CRO/CMO Council and sits on the Industrial Advisory Board for the Department of Chemical Engineering at UMass, Amherst. Ed is also a long standing member of the American Chemical Society and advises the Bulk Pharmaceutical Task Force of the Society of Chemical Manufacturer’s and Affiliates (SOCMA)...

Do you have questions? Talk to Ed.